Pfizer, Inc. (PFE) Given a $35.00 Price Target by Jefferies Group LLC Analysts
Pfizer, Inc. (NYSE:PFE) has been given a $35.00 price objective by Jefferies Group LLC in a research note issued to investors on Thursday. The brokerage presently has a “neutral” rating on the biopharmaceutical company’s stock. Jefferies Group LLC’s target price would suggest a potential upside of 5.29% from the company’s previous close.
A number of other brokerages have also issued reports on PFE. Cowen and Company set a $43.00 price objective on shares of Pfizer and gave the company a “buy” rating in a report on Monday, August 14th. Berenberg Bank reissued a “hold” rating and issued a $36.00 price objective (down previously from $39.00) on shares of Pfizer in a report on Tuesday, August 15th. Zacks Investment Research raised shares of Pfizer from a “sell” rating to a “hold” rating in a report on Friday, July 14th. BidaskClub lowered shares of Pfizer from a “sell” rating to a “strong sell” rating in a report on Thursday, July 13th. Finally, Morgan Stanley reissued a “neutral” rating and issued a $35.00 price objective (down previously from $38.00) on shares of Pfizer in a report on Monday, June 12th. Two research analysts have rated the stock with a sell rating, eleven have issued a hold rating and ten have assigned a buy rating to the stock. The company presently has an average rating of “Hold” and an average price target of $37.61.
Pfizer (PFE) remained flat at $33.24 during trading on Thursday. 8,803,344 shares of the stock traded hands. The stock has a 50-day moving average of $33.26 and a 200 day moving average of $33.41. Pfizer has a 12 month low of $29.83 and a 12 month high of $35.19. The stock has a market capitalization of $197.69 billion, a P/E ratio of 24.32 and a beta of 1.00.
Pfizer (NYSE:PFE) last announced its quarterly earnings data on Tuesday, August 1st. The biopharmaceutical company reported $0.67 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.65 by $0.02. Pfizer had a net margin of 15.84% and a return on equity of 24.51%. The firm had revenue of $12.90 billion during the quarter, compared to analyst estimates of $13.08 billion. During the same quarter in the prior year, the firm posted $0.64 earnings per share. Pfizer’s quarterly revenue was down 1.9% on a year-over-year basis. On average, equities analysts predict that Pfizer will post $2.56 EPS for the current year.
TRADEMARK VIOLATION NOTICE: This article was first posted by American Banking News and is the property of of American Banking News. If you are accessing this article on another site, it was illegally copied and reposted in violation of United States and international copyright legislation. The legal version of this article can be read at https://www.americanbankingnews.com/2017/08/24/pfizer-inc-pfe-given-a-35-00-price-target-by-jefferies-group-llc-analysts.html.
In related news, insider Alexander R. Mackenzie sold 15,000 shares of the firm’s stock in a transaction that occurred on Monday, August 7th. The shares were sold at an average price of $33.50, for a total value of $502,500.00. Following the sale, the insider now owns 151,474 shares of the company’s stock, valued at $5,074,379. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, CEO Ian C. Read sold 96,950 shares of the firm’s stock in a transaction that occurred on Friday, August 4th. The shares were sold at an average price of $34.00, for a total transaction of $3,296,300.00. The disclosure for this sale can be found here. Insiders have sold 120,014 shares of company stock worth $4,062,493 in the last three months. Corporate insiders own 0.06% of the company’s stock.
Hedge funds have recently modified their holdings of the stock. Asset Planning Services Ltd. boosted its stake in shares of Pfizer by 4.9% in the first quarter. Asset Planning Services Ltd. now owns 2,961 shares of the biopharmaceutical company’s stock valued at $101,000 after buying an additional 137 shares during the period. Shine Investment Advisory Services Inc. purchased a new stake in shares of Pfizer during the second quarter valued at $102,000. Mckinley Capital Management LLC Delaware purchased a new stake in shares of Pfizer during the second quarter valued at $103,000. D. Scott Neal Inc. boosted its stake in shares of Pfizer by 19.3% in the second quarter. D. Scott Neal Inc. now owns 3,112 shares of the biopharmaceutical company’s stock valued at $105,000 after buying an additional 504 shares during the period. Finally, Orrstown Financial Services Inc. boosted its stake in shares of Pfizer by 23.0% in the first quarter. Orrstown Financial Services Inc. now owns 3,275 shares of the biopharmaceutical company’s stock valued at $112,000 after buying an additional 612 shares during the period. 69.94% of the stock is currently owned by hedge funds and other institutional investors.
Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).
Receive News & Ratings for Pfizer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer Inc. and related companies with MarketBeat.com's FREE daily email newsletter.